|
In Vitro Activity of the New Azole Isavuconazole (BAL 4815) Compared with Six other Antifungal Agents against 155 Cryptococcus neoformans Isolates from Cuba (click for details) |
|
|
|
In Vitro Activity of the New Azole BAL4815 and other Antifungal Agents against Candida Bloodstream Isolates (click for details) |
|
|
|
Concomittant N-Acetylcystein for the Prevention of the Amphotericin B Induced Renal Tubular Apoptosis.
(click for details) |
|
|
|
In Vitro Activities of Statins (Anti-Cholesterol Drugs) Alone and in Combination with Antifungal Drugs against Aspergillus Species.
(click for details) |
|
|
|
Digestion of Echinocandins.
(click for details) |
|
|
|
Mycograb in Combination with Caspofungin in Murine Models of Candidiasis. (click for details) |
|
|
|
Posaconazole (POS) Compared to High Dose Lipid Formulations of Amphotericin B (HD-LPAMB) as Salvage Therapy for Invasive Aspergillosis (IA) in Patients (pts) with Hematologic Malignancy (HM).
(click for details) |
|
|
|
Susceptibility of Candida Blood Isolates to Fluconazole (FLU) and Voriconazole (VOR) in Russia.
(click for details) |
|
|
|
Comparative Efficacy of Concomitant vs Sequential Therapy with Liposomal Amphotericin B (LAmB) and Micafungin (Mc) in Murine Systemic Aspergillosis.
(click for details) |
|
|
|
Comparison of Prophylactic and Therapeutic Liposomal Amphotericin B (LAmB) Treatment in Murine Pulmonary Aspergillosis (PA).
(click for details) |
|
|
